RUNX2 and osteosarcoma: Additionally, RUNX2 was found to be overexpressed in chemoresistant osteosarcomas [92], non-small cell lung cancers (NSCLCs) [93], and breast cancers [94], thereby raising the legitimate question of its role as a tumor-driving transcription factor.